0
0
0
0
1
2
3
$0
Is Pfizer solid or fragile? The Finex Financial Health Scanner reads PFE's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $62.6B |
|---|---|
| Net income | $7.8B |
| Operating margin | 22.8% |
| Net margin | 12.5% |
| Cash and investments | $13.6B |
| Total debt | $68.4B |
| Free cash flow | $13.0B |
| Revenue growth (1 year) | -1.6% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.